MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ
1.750
-0.030
-1.69%
After Hours: 1.770 +0.02 +1.14% 19:59 08/21 EDT
OPEN
1.810
PREV CLOSE
1.780
HIGH
1.840
LOW
1.725
VOLUME
4.18M
TURNOVER
--
52 WEEK HIGH
19.40
52 WEEK LOW
1.310
MARKET CAP
65.49M
P/E (TTM)
-1.1866
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TENX last week (0810-0814)?
Weekly Report · 6d ago
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Barchart · 08/16 16:38
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
Barchart · 08/14 09:53
Tenax Therapeutics Price Target Cut to $5.00/Share From $27.00 by Chardan Capital
Dow Jones · 08/11 16:12
Tenax Therapeutics Cut to Neutral From Buy by Chardan Capital
Dow Jones · 08/11 16:12
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 08/11 16:04
Tenax Therapeutics Price Target Cut to $4.00/Share From $35.00 by Canaccord Genuity
Dow Jones · 08/11 16:04
Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5
Benzinga · 08/11 16:02
More
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Webull offers Tenax Therapeutics Inc stock information, including NASDAQ: TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.